Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5168130 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL4778591 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL741996 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL4773208 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL2805480 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL1535294 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL5651326 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL514304 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL581065 | 1.00 | DUT (0.37) | DUT | |
| SCHEMBL1535321 | 1.00 | DUT (0.37) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117736252-A | Fulvestrant key intermediate impurity and preparation method and application thereof | 杭州新博思生物医药有限公司 | 2024-03-22 | — | — | CN | claimed |
| WO-2017064724-A1 | NOVEL PROCESS AND INTERMEDIATES FOR THE PREPARATION OF HIGH PURITY FULVESTRANT | NATCO PHARMA LTD (IN) | 2017-04-20 | — | — | WO | claimed |
| CN-118930598-A | Fulvestrant Process for the preparation of intermediates | 杭州莱尼科技有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-117736252-A | Fulvestrant key intermediate impurity and preparation method and application thereof | 杭州新博思生物医药有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2020245291-A1 | PYRROLE DERIVATIVES AS ACC INHIBITORS | ALMIRALL, S.A. (ES) | 2020-12-10 | — | — | WO | disclosed |
| WO-2017064724-A1 | NOVEL PROCESS AND INTERMEDIATES FOR THE PREPARATION OF HIGH PURITY FULVESTRANT | NATCO PHARMA LTD (IN) | 2017-04-20 | — | — | WO | disclosed |
| EP-2183267-B1 | PROCESS FOR PREPARING 7-ALPHA-[9-(4,4,5,5,5-PENTAFLUOROTHIOPENTYL) NONYL]ESTRA-1,3,5(10)-TRIENE-3,17-BETA-DIOL | IND CHIMICA SRL (IT) | 2014-08-20 | — | — | EP | disclosed |
| US-20110319446-A1 | BICYCLO[2.2.1]HEPT-7-YLAMINE DERIVATIVES AND THEIR USES | ARGENTA DISCOVERY LTD. (GB) | 2011-12-29 | — | — | US | disclosed |
| US-20110319446-A1 | BICYCLO[2.2.1]HEPT-7-YLAMINE DERIVATIVES AND THEIR USES | ARGENTA DISCOVERY LTD. (GB) | 2011-12-29 | — | — | US | disclosed |
| US-7994211-B2 | Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses | ARGENTA DISCOVERY LIMITED (GB) | 2011-08-09 | — | — | US | disclosed |
| US-7994211-B2 | Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses | ARGENTA DISCOVERY LIMITED (GB) | 2011-08-09 | — | — | US | disclosed |
| US-20060030552-A1 | Process for the preparation of 7alpha-alkylated 19-norsteroids | SICOR, INC. | 2006-02-09 | — | — | US | disclosed |
| US-6780855-B2 | TREATING A PATIENT SUFFERING FROM AN ESTROGEN DEPENDENT-DISEASE | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-08-24 | — | — | US | disclosed |
| US-6767903-B1 | ANTIANDROGEN THERAPY FOR PROSTATE CANCER | SCHERING AG (DE) | 2004-07-27 | — | — | US | disclosed |
| US-6596885-B2 | As antiestrogenic and anti-proliferative agent | AVENTIS PHARMA S.A. (FR) | 2003-07-22 | — | — | US | disclosed |
| US-20030069434-A1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA- SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-04-10 | — | — | US | disclosed |
| EP-1140972-B1 | NEW 7-ALPHA, 17-ALPHA-BIS-ALKYLATED TESTOSTERONE DERIVATIVES AND THEIR USE IN LONG-TERM THERAPY OF ANDROGEN-DEPENDENT DISEASES | SCHERING AG (DE) | 2003-03-05 | — | — | EP | disclosed |
| EP-1042355-B1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | SCHERING AG (DE) | 2003-02-12 | — | — | EP | disclosed |
| US-20020072624-A1 | New 19-Nor steroids having a thiocarbonated chain in position 11beta, their preparation process and the intermediates of this process, their use as medicaments and compositions | ROUSSEL UCLAF | 2002-06-13 | — | — | US | disclosed |
| US-6281204-B1 | ANTIESTROGENS | Roussel, Hoechst Marion (FR) | 2001-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319446-A1 | BICYCLO[2.2.1]HEPT-7-YLAMINE DERIVATIVES AND THEIR USES | CHRM2, CHRM3, CHRM1 | DUT 3835/4885 |
| US-20020072624-A1 | New 19-Nor steroids having a thiocarbonated chain in position 11beta, their preparation process and the intermediates of this process, their use as medicaments and compositions | HSD17B11, NR5A1, CYP19A1 | DUT 423/4885 |
| US-20060030552-A1 | Process for the preparation of 7alpha-alkylated 19-norsteroids | CYP19A1, CYP17A1, CYP4A11 | DUT 499/4885 |
| US-20030069434-A1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA- SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | CYP19A1, HSD17B11, NR5A1 | DUT 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.